相关实验视频
Updated: Jan 18, 2026

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
针对长非编码RNA的小干扰RNA疗法SMILR用于冠状动脉旁路移植失败的治疗干预
Simon D Brown1, Anna L Malinowska2, Matthew Bennett1
1BHF Centre for Cardiovascular Science, Queens Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom.
研究人员开发了一种新的siRNA疗法,BHF7,以准SMILR,长非编码RNA驱动平滑肌肉细胞增殖. 这种疗法有望通过改善移植通透性来预防冠状动脉旁路移植失败.
科学领域:
- 生物医学工程 生物医学工程
- 分子生物学分子生物学
- 心血管研究研究心血管研究
背景情况:
- 冠状动脉旁路移植 (CABG) 失败通常是由过度的血管光滑肌细胞 (SMC) 增殖引起的.
- 长非编码RNA的SMILR驱动SMC的扩散,并导致CABG的失败.
研究的目的:
- 为了确定一个领先的小干扰RNA (siRNA) 针对SMILR进行临床开发.
- 评估一种新型siRNA疗法的有效性和安全性,以预防CABG失败.
主要方法:
- 设计和合成了一个76个SMILR向siRNAs的库.
- 在体外和体外使用人静脉模型识别并测试了SiRNA BHF7.
- 利用RNA测序,道染色和ELISA来评估基因表达,增殖和细胞毒性.
主要成果:
- 在体外和体外,BHF7有效地抑制了SMILR的表达,并阻止了SMC的扩散.
- RNA测序显示,BHF7降低了与繁殖相关的基因的下调,而不会诱导干扰素或亡.
- 在接受治疗的组织中,BHF7没有显示出细胞毒性反应.
结论:
- BHF7是一种强效和特定的siRNA治疗候选物,可以预防新密的形成和CABG失败.
- 临床前数据支持进一步调查BHF7作为一种ex vivoRNA治疗药物,用于改善CABG移植通透性.
更多相关视频
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
07:01Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
相关概念视频
Experimental RNAi
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Small interfering RNAs (siRNA)
MicroRNAs
MicroRNAs